Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Hospira

- PMLiVE

BioNTech bolsters COVID-19 vaccine capacity with Novartis deal

Deal will expand production capacity for BNT162b2 candidate

- PMLiVE

Novavax CEO anticipates filing COVID-19 vaccine for approval in December

Pfizer also announces over 50% enrolment in COVID-19 vaccine trial

- PMLiVE

Novartis’ asciminib tops Pfizer’s Bosulif in chronic myeloid leukaemia trial

Drug improved major molecular response compared to existing med

- PMLiVE

Novartis wins FDA approval for relapsing MS drug Kesimpta

Swiss pharma company is expecting EU approval for treatment next year

- PMLiVE

Pifzer, BioNTech eye October approval for mRNA-based COVID-19 vaccine

Companies share additional phase 1 safety and tolerability data

- PMLiVE

Novartis builds its case for novel MS treatment ofatumumab

Detailed results from phase 3 studies published in NEJM

- PMLiVE

Pfizer’s Xalkori follow-up Lorbrena hits the mark in first-line lung cancer

ALK inhibitor improved progression-free survival in first-line setting

- PMLiVE

AbbVie, Amgen and Takeda team up for joint COVID-19 trial

Collaborative trial will evaluate three anti-inflammatory drugs

- PMLiVE

NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer

Picks up approval as a first-line treatment for advanced cancer

- PMLiVE

Pfizer, BioNTech identify and advance lead COVID-19 vaccine candidate

Companies pick the most promising candidate to take into phase 2/3

- PMLiVE

Biogen plans Spinraza study in SMA patients treated with Novartis’ Zolgensma

Company aims to extend market reach

- PMLiVE

US government pays $1.95bn for Pfizer/BioNTech’s COVID-19 vaccine

Initial order includes 100 million doses

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links